Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
NeuroSense Therapeutics Ltd. Warrant (NRSNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: NRSNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -88.45% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.6 | 52 Weeks Range 0.10 - 1.06 | Updated Date 06/21/2025 |
52 Weeks Range 0.10 - 1.06 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -159.5% | Return on Equity (TTM) -2478.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 11925007 |
Shares Outstanding - | Shares Floating 11925007 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NeuroSense Therapeutics Ltd. Warrant
Company Overview
History and Background
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for neurodegenerative diseases. Their warrant provides the holder the right to purchase shares of NeuroSense common stock at a specified price within a certain period.
Core Business Areas
- Drug Development: Developing therapeutics for neurodegenerative diseases.
- Research and Development: Conducting research to identify novel drug candidates.
Leadership and Structure
Information regarding NeuroSense Therapeutics Ltd.'s leadership team and organizational structure can be found on their investor relations website or in their SEC filings.
Top Products and Market Share
Key Offerings
- PrimeC: PrimeC is NeuroSense's lead drug candidate being developed for Amyotrophic Lateral Sclerosis (ALS). Clinical trial data is being assessed. Competitors include Biogen (Tofersen), Amylyx Pharmaceuticals (Relyvrio).
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in neurodegenerative diseases, is characterized by high unmet needs, lengthy development timelines, and significant regulatory hurdles.
Positioning
NeuroSense is a clinical-stage company attempting to bring new drugs to market in this difficult area. Their competitive advantage relies on the efficacy and safety of their drug candidates.
Total Addressable Market (TAM)
The global market for neurodegenerative disease therapies is substantial, potentially reaching billions of dollars. NeuroSense's TAM depends on the indications they target and their success in clinical trials.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates
- Experienced management team
- Focus on high unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Competition from larger pharmaceutical companies
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Government grants and funding
Threats
- Clinical trial failures
- Regulatory delays
- Competition from other companies in the field
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- ALKS
- IONS
Competitive Landscape
NeuroSense competes with larger, more established pharmaceutical companies. Their success depends on the efficacy and safety of their treatments and their ability to secure funding.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth is minimal, as the company is pre-revenue and focused on R&D.
Future Projections: Future growth depends on positive clinical trial outcomes, regulatory approvals, and commercialization of its drug candidates.
Recent Initiatives: Focus on ongoing clinical trials for PrimeC and expansion of their pipeline.
Summary
NeuroSense Therapeutics is a risky, early-stage biotech company focused on neurodegenerative diseases. The company depends heavily on the success of their clinical trials for PrimeC. Future projections depend on the approval and commercialization of PrimeC. The company will have to look out for possible threats such as regulatory delays and strong competition from larger pharmaceutical companies. Strong financial performance will be key to making sure the company does not run out of capital.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q), Company website, Third-party financial data providers
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment in clinical stage companies is high risk. Market share data is based on assumptions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NeuroSense Therapeutics Ltd. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-12-09 | Co-Founder, CEO & Director Mr. Alon Ben-Noon | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.neurosense-tx.com |
Full time employees 17 | Website https://www.neurosense-tx.com | ||
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.